A growing body of evidence suggests the existence of abnormalities in the immune system of schizophrenic patients. The current study examined serum levels of interleukin (IL) -1β, IL-6, IL-2,interferon(IFN) -γ, and tumor necrosis factor(TNF)-α in schizophrenic patients before and after treatment with risperidone and correlated levels of these cytokines with symptomatology. The study group consisted of 24 schizophrenic patients as defined by Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria and 24 healthy controls. Serum cytokine levels were examined using enzyme-linked immunosorbent assay (ELISA). Schizophrenic symptomatology was assessed with the Positive and Negative Syndrome Scale (PANSS) questionnaire. The serum levels of TNF-α, IL-1β and IL-6 were significantly higher in participants before treatment compared with the healthy controls and after treatment (p<0.001). IFN-γ and IL-2 levels were significantly lower in participants after treatment compared with before treatment and the healthy controls (p<0.001). Except for IL-6 (p<0.05), there was no significant difference in the levels of TNF-α and IL-1β between the patients receiving treatment and the healthy subjects. Moreover, there was no significant difference in levels of IFN-γ and IL-2 between patients before treatment and the healthy subjects. There were no significant correlations between the concentration of cytokines studied and the PANSS. Positive intercorrelations between the production of IFN-γ and IL-2 were detected for sums of all groups(r=0.33, p=0.005). Clinical improvement of treated patients was associated with a reduction in the studied cytokines. It seems that changes in the cytokines level may play a significant role in the psychopathology of these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.18502/ijaai.v18i3.1119 | DOI Listing |
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Neuropsychopharmacol Hung
December 2024
Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.
Med Health Care Philos
January 2025
Université de Genève, Genève, Switzerland.
This paper seeks to determine the extent to which individuals with borderline personality disorders can be held morally responsible for a particular subset of their actions: disproportionate anger, aggressions and displays of temper. The rationale for focusing on these aspects lies in their widespread acknowledgment in the literature and their plausible primary association with blame directed at BPD patients. BPD individuals are indeed typically perceived as "difficult patients" (Sulzer 2015:82; Bodner et al.
View Article and Find Full Text PDFBrain Behav
January 2025
Computational and Artificial Intelligence Department, Institute of Cognitive Science Studies, Tehran, Iran.
Purpose: The neurobiological heterogeneity present in schizophrenia remains poorly understood. This likely contributes to the limited success of existing treatments and the observed variability in treatment responses. Our objective was to employ magnetic resonance imaging (MRI) and machine learning (ML) algorithms to improve the classification of schizophrenia and its subtypes.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Clinical Neuropsychiatry, Medical University of Lublin, ul. Głuska 1, 20-439, Lublin, Poland.
Schizophrenia is a serious mental disorder with a complex neurobiological background and a well-defined psychopathological picture. Despite many efforts, a definitive disease biomarker has still not been identified. One of the promising candidates for a disease-related biomarker could involve retinal morphology , given that the retina is a part of the central nervous system that is known to be affected in schizophrenia and related to multiple illness features.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!